Sanofi's mRNA Covid-19 vaccine candidate not ready this year, CEO says | The Business Standard
Skip to main content
  • Latest
  • Economy
    • Banking
    • Stocks
    • Industry
    • Analysis
    • Bazaar
    • RMG
    • Corporates
    • Aviation
  • Videos
    • TBS Today
    • TBS Stories
    • TBS World
    • News of the day
    • TBS Programs
    • Podcast
    • Editor's Pick
  • World+Biz
  • Features
    • Panorama
    • The Big Picture
    • Pursuit
    • Habitat
    • Thoughts
    • Splash
    • Mode
    • Tech
    • Explorer
    • Brands
    • In Focus
    • Book Review
    • Earth
    • Food
    • Luxury
    • Wheels
  • Subscribe
    • Epaper
    • GOVT. Ad
  • More
    • Sports
    • TBS Graduates
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • Gallery
    • Long Read
    • Interviews
    • Offbeat
    • Magazine
    • Climate Change
    • Health
    • Cartoons
  • বাংলা
The Business Standard

Saturday
July 12, 2025

Sign In
Subscribe
  • Latest
  • Economy
    • Banking
    • Stocks
    • Industry
    • Analysis
    • Bazaar
    • RMG
    • Corporates
    • Aviation
  • Videos
    • TBS Today
    • TBS Stories
    • TBS World
    • News of the day
    • TBS Programs
    • Podcast
    • Editor's Pick
  • World+Biz
  • Features
    • Panorama
    • The Big Picture
    • Pursuit
    • Habitat
    • Thoughts
    • Splash
    • Mode
    • Tech
    • Explorer
    • Brands
    • In Focus
    • Book Review
    • Earth
    • Food
    • Luxury
    • Wheels
  • Subscribe
    • Epaper
    • GOVT. Ad
  • More
    • Sports
    • TBS Graduates
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • Gallery
    • Long Read
    • Interviews
    • Offbeat
    • Magazine
    • Climate Change
    • Health
    • Cartoons
  • বাংলা
SATURDAY, JULY 12, 2025
Sanofi's mRNA Covid-19 vaccine candidate not ready this year, CEO says

Coronavirus chronicle

Reuters
14 February, 2021, 11:10 am
Last modified: 14 February, 2021, 11:15 am

Related News

  • Novavax signs Covid-19 license deal with Sanofi, removes doubt about business viability
  • Bolsonaro home raided, phone seized in Brazil vaccine records probe
  • WHO provides 11 lakh bivalent vaccines to Bangladesh: Minister
  • Incepta Pharma abandons Covid vaccine plan
  • AstraZeneca, Moderna recipients to receive Pfizer vaccine to mix-and-match

Sanofi's mRNA Covid-19 vaccine candidate not ready this year, CEO says

Clinical trials of this vaccine are expected to start this quarter

Reuters
14 February, 2021, 11:10 am
Last modified: 14 February, 2021, 11:15 am
A researcher works in an industrial development laboratory at the vaccine unit of French drugmaker Sanofi's Pasteur plant in Marcy-l'Etoile, near Lyon, France June 16, 2020. REUTERS/Gonzalo Fuentes/File Photo
A researcher works in an industrial development laboratory at the vaccine unit of French drugmaker Sanofi's Pasteur plant in Marcy-l'Etoile, near Lyon, France June 16, 2020. REUTERS/Gonzalo Fuentes/File Photo

A Covid-19 vaccine candidate developed by Sanofi and US group Translate Bio "will not be ready this year," the French drugmaker's chief executive told Le Journal du Dimanche newspaper.

Clinical trials of this vaccine, which will be based on a technology known as mRNA -- on which lean approved vaccines of Pfizer/BioNTech and Moderna --, are expected to start this quarter.

In December last year, Sanofi had said it was targeting "earliest potential approval" of the shot in the second half of 2021, following positive preclinical data.

The Business Standard Google News Keep updated, follow The Business Standard's Google news channel

"This vaccine will not be ready this year, but it could be of use at a later stage all the more if the fight against variants was to continue," Paul Hudson was quoted as saying.

The CEO gave no other details. Officials at Sanofi were not available for comment.

The news could mark another blow for Sanofi, already embattled with a delay for another Covid-19 vaccine candidate it hopes to bring to patients and for which the company has teamed up with Britain's GlaxoSmithKline.

The two groups stunned investors last year by warning their traditional, protein-based Covid-19 jab showed an insufficient immune response in older people, delaying its launch towards the end of 2021.

To appease critics, Sanofi said last month it had agreed to fill and pack millions of doses of the Pfizer/BioNTech vaccine from July.

Some 108 million people have been reported to be infected by the novel coronavirus globally and more than 2.4 million have died since first cases were identified in China in December 2019, according to a Reuters tally.

Countries worldwide have since the beginning of the year embarked on mass vaccination programmes, with mixed results, and are now confronted with the emergence of several variant strains which forces them to move even more quickly.

Top News

mRNA Covid-19 vaccine / Sanofi France / Sanofi / Coronavirus Vaccine / covid-19 vaccine / Covid-19 Vaccine Shot / Vaccine availability / Vaccine distribution

Comments

While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.

Top Stories

  • Representational image
    In addition to 35% tariff, US demands 40% local value addition for 'Made in Bangladesh' goods
  • Kunming rising: China's emerging healthcare hub draws Bangladeshi patients
    Kunming rising: China's emerging healthcare hub draws Bangladeshi patients
  • Representational image. Photo: Collected
    2nd round of US-Bangladesh tariff talks set to conclude today as business leaders await breakthrough

MOST VIEWED

  • In terms of stream of education, girls maintained their excellence as well. Photo: TBS
    SSC 2025: Girls dominate boys by over 5%
  • Photo: Mohammad Minhaj Uddin/TBS
    SSC, equivalent results: Pass rate drops to 68.45%, GPA-5 also declines
  • The overall pass rate across all boards this year, 68.45%, is significantly lower than last year's. Photo: Focus Bangla
    SSC 2025: Rajshahi board records highest pass rate, Barishal lowest
  • How S Alam’s Global Islami Bank cooked Tk2,259cr loss into Tk128cr profit
    How S Alam’s Global Islami Bank cooked Tk2,259cr loss into Tk128cr profit
  • Representational image. Photo: TBS
    SSC 2025: 73.63% pass rate among technical students, 68.09% at Madrasahs
  • Economist Abul Barkat; Photo: Courtesy
    Economist Abul Barkat arrested in graft case

Related News

  • Novavax signs Covid-19 license deal with Sanofi, removes doubt about business viability
  • Bolsonaro home raided, phone seized in Brazil vaccine records probe
  • WHO provides 11 lakh bivalent vaccines to Bangladesh: Minister
  • Incepta Pharma abandons Covid vaccine plan
  • AstraZeneca, Moderna recipients to receive Pfizer vaccine to mix-and-match

Features

Kunming rising: China's emerging healthcare hub draws Bangladeshi patients

Kunming rising: China's emerging healthcare hub draws Bangladeshi patients

6h | Panorama
Photo: Collected/BBC

What Hitler’s tariff policy misfire can teach the modern world

1d | The Big Picture
Illustration: TBS

Behind closed doors: Why women in Bangladesh stay in abusive marriages

1d | Panorama
Purbachl’s 144-acre Sal forest is an essential part of the area’s biodiversity. Within it, 128 species of plants and 74 species of animals — many of them endangered — have been identified. Photo: Syed Zakir Hossain/TBS

A forest saved: Inside the restoration of Purbachal's last Sal grove

1d | Panorama

More Videos from TBS

Renowned economist Abul Barkat imprisoned

Renowned economist Abul Barkat imprisoned

4h | TBS Today
All of Iran's uranium still intact, Israel claims

All of Iran's uranium still intact, Israel claims

4h | TBS World
Trump-Netanyahu in new strategy on Gaza issue

Trump-Netanyahu in new strategy on Gaza issue

6h | TBS World
Shocking science: why birds stay safe on electricity lines

Shocking science: why birds stay safe on electricity lines

7h | TBS Stories
EMAIL US
contact@tbsnews.net
FOLLOW US
WHATSAPP
+880 1847416158
The Business Standard
  • About Us
  • Contact us
  • Sitemap
  • Advertisement
  • Privacy Policy
  • Comment Policy
Copyright © 2025
The Business Standard All rights reserved
Technical Partner: RSI Lab

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - oped.tbs@gmail.com

For advertisement- sales@tbsnews.net